Proton pump inhibitors — omeprazole, esomeprazole, pantoprazole, rabeprazole, and lansoprazole — share a benzimidazole sulfoxide bridge built by oxidizing a corresponding sulfide precursor. DMSO-based oxidation systems deliver that one oxygen cleanly and are widely used across the PPI class.
R–S–R′ + (CH3)2SO(COCl)2 or carbodiimide activator, −10 to 25 °C→R–SO–R′ + (CH3)2S
Reaction 1: DMSO-mediated sulfide-to-sulfoxide oxidation (PPI synthesis)
Reaction Mechanism and Conditions
In the DMSO-based system, an activator such as oxalyl chloride or a carbodiimide first reacts with DMSO to generate an electrophilic sulfonium intermediate, analogous to the Swern activation. The sulfide sulfur of the benzimidazole precursor attacks this intermediate, forming an alkoxysulfonium species that transfers one oxygen equivalent to the sulfur. Base-induced elimination then releases the sulfoxide product and dimethyl sulfide as byproduct.
Temperature control is the key process parameter: the oxidation is typically run between −10 °C and 25 °C, with the lower end favored for substrates prone to sulfone formation. A slight excess of the DMSO–activator complex (1.05–1.2 equivalents) ensures complete sulfide conversion without pushing into over-oxidation. The reaction is monitored by HPLC for both residual sulfide and sulfone impurity, with the sulfone held below 0.5% to meet pharmacopeial limits.
Where DMSO-Based Sulfoxidation Is Used
Every major PPI is manufactured from a benzimidazole sulfide oxidized to the corresponding sulfoxide. The critical requirement is selectivity: the reaction must stop at the sulfoxide and hold the over-oxidized sulfone impurity below roughly 0.5% of the drug substance, because the sulfoxide sulfur is itself oxidizable.
The same selective-sulfoxide chemistry extends to modafinil, a wakefulness-promoting agent whose active benzhydryl sulfinyl acetamide is made by oxidizing the corresponding thioacetamide precursor. For esomeprazole, the stereogenic sulfoxide demands an enantioselective oxidation that still operates within the DMSO-mediated impurity-control framework.
Drug-by-Drug Applications
Pantoprazole and rabeprazole carry additional alkoxy substituents that influence reactivity, so the chosen activator and temperature are tuned to each substrate’s impurity profile. Across the class, process development converges on a single clean sulfoxide with minimal sulfone and minimal unreacted sulfide.
| Drug | Class | DMSO sulfoxidation step |
|---|---|---|
| Omeprazole / esomeprazole | PPI API | Benzimidazole sulfide → sulfoxide |
| Pantoprazole / rabeprazole / lansoprazole | PPI API | Sulfide → sulfoxide, sulfone < 0.5% |
| Modafinil | CNS API | Thioacetamide → sulfinyl acetamide |
Table 1: Representative DMSO-mediated sulfoxidation applications
Why DMSO Systems Rather Than Peracids
Peracids such as m-CPBA are strong oxidants that, without tight temperature control, push past the sulfoxide into the sulfone while generating a stoichiometric carboxylic-acid waste stream. DMSO-based activation transfers one oxygen equivalent to the more nucleophilic sulfide sulfur and leaves the benzimidazole and pyridine nitrogens untouched.
Hydrogen peroxide under titanium catalysis is the alternative for enantioselective batches, but where sulfone control is the dominant requirement, mild DMSO activation remains the preferred route. The trade-off is the dimethyl sulfide byproduct, handled by closed, scrubbed equipment and accepted against the clean sulfoxide yield.
References
- Lagerström, E. et al. (Astra Hässle), U.S. Patent 4,255,431, 1981.
- Brieger, U. et al. (Byk Gulden), U.S. Patent 4,758,579, 1988.
- Lafon, M. U.S. Patent 4,177,290, 1979 (modafinil).